BRIEF-NeuroVive Pharmaceutical enters into global licensing agreement with Yungjin Pharm
May 2 Yungjin Pharm Co Ltd:
* announced it has entered into global licensing agreement on Yungjin Pharm's compound KL1333 for genetic mitochondrial disorders
* will now initiate activities in preparation for next clinical study in Europe and/or in U.S.
* NeuroVive will pay Yungjin Pharm upfront payments of $1 million at signing
* NeuroVive will pay Yungjin Pharm additional $1 million after completion of a successful phase I clinical trial Source text for Eikon: Further company coverage:
BRIEF-Allegheny Technologies, units enter into second amendment
* Allegheny Technologies - on June 21, 2017, co, units entered into a second amendment to revolving credit and security agreement - SEC filing